| | |
Neuropsychiatric disorders
|
p
|
|---|
| |
No
| |
Yes
|
|---|
|
N
|
Median (IQR)
|
N
|
Median (IQR)
|
|---|
|
Day-3
|
37
|
1.61 (1.37-2.29)
|
125
|
2.29 (1.52-2.92)
|
0.02
|
|
week-1
|
28
|
1.86 (1.43-2.55)
|
80
|
2.26 (1.67-3.1)
|
0.13
|
|
week-2
|
40
|
1.69 (1.32-2.15)
|
111
|
2.22 (1.41-3.21)
|
0.03
|
|
week-4
|
40
|
1.57 (1.31-2.25)
|
110
|
2.49 (1.58-3.57)
|
0.002
|
|
week-6
|
36
|
1.8 (1.42-2.61)
|
86
|
2.37 (1.66-4.25)
|
0.008
|
|
week-8
|
45
|
1.64 (1.36-2.81)
|
121
|
2.31 (1.53-3.21)
|
0.09
|
|
week-12
|
41
|
1.84 (1.45-2.57)
|
101
|
2.57 (1.68-4.19)
|
0.03
|
- Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7,8 and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log transformed efavirenz concentration was used using independent sample T-test.
